Sexual Dysfunctions, Psychological Clinical Trial
Official title:
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional Platelet Rich Plasma for Peyronie's Disease
The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.
Status | Recruiting |
Enrollment | 22 |
Est. completion date | January 15, 2025 |
Est. primary completion date | July 15, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Be able to provide written informed consent 2. Have a diagnosis of PD with evidence of stable disease as determined by the investigator 3. Patient must have palpable penile plaque 4. Penile curvature deformity of >30° to <90° 5. Agree to comply with all study related tests/procedures. 6. Prior intralesional platelet rich plasma treatment within the past 18 months and desire secondary treatment of penile curvature Exclusion Criteria: 1. Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting, penile prosthesis. 2. Previous intralesional injection therapy with CCH for PD within six months. Patients with failed therapy greater than six months ago may be included. 3. Previous history of priapism or penile fracture 4. PD characterized by a ventral plaque 5. Severe erectile dysfunction as characterized with an IIEF score = 12 6. Hour-glass deformity 7. Unwilling to participate 8. Medically unfit for sexual intercourse as deemed by the principal investigator 9. Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with autologous PRP injection therapy. 10. Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study. |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
United States | University of Miami - Desai Sethi Urology Institute | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami | Endo Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Treatment Related Adverse Events | To determine number of treatment related adverse events. Safety will be evaluated via the incidence of adverse events as assessed by treating physician | up to 6 months (post-intervention) | |
Primary | Percent change of penile curvature in degrees. | Treatment efficacy of CCH will be assessed via the percentage of participants achieving degree change in penile curvature from baseline. Degree of curvature will be measured using a goniometer with the aid of injection of vasoactive substance into the penis. | Baseline up to 6 months | |
Secondary | Change in Peyronie's Disease Questionnaire (PDQ) sub-domain scores (Psychological and Physical Symptoms, Symptom Bother). | Treatment efficacy will be assessed via the change of participants achieving any decrease in Peyronie's disease Questionnaire (PDQ) sub-domain scoring from baseline. The sub-domains that will be assessed in primary outcome is Psychological and Physical Symptoms and Symptom Bother. PDQ is a validated 15-item questionnaire that assess Psychological and Physical Symptoms, Symptom Bother, and Penile Pain subdomains. The Psychological and Physical Symptoms subdomain is measured from 0 to 24 (most severe symptoms). Symptom Bother subdomain is measured from 0 to 30 (most severe pain). | Baseline, 6 months. | |
Secondary | Changes in International Index of Erectile Function - Erectile Function (IIEF-EF) scores | IIEF-EF is a 5-item subdomain self-evaluation questionnaire of erectile function. Each item is scored from 0-5 with the total score ranging from 0-25 with the higher score indicating better erectile function. | Baseline, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00996164 -
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00996372 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01188720 -
Sexual Health on Antidepressants Through Physical Exercise
|
N/A | |
Completed |
NCT00175539 -
Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties
|
N/A | |
Completed |
NCT04792177 -
Internet-based Emotion Regulation Intervention for Sexual Health
|
N/A | |
Completed |
NCT02381912 -
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
|
N/A | |
Completed |
NCT03241524 -
Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women
|
N/A | |
Completed |
NCT00491829 -
Flibanserin Versus Placebo in Premenopausal Women With HSDD
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
Recruiting |
NCT05489133 -
Early Psychological Intervention After Rape
|
N/A | |
Completed |
NCT03775239 -
Mindfulness as Treatment of Sexological Problems
|
N/A | |
Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
Completed |
NCT01188603 -
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 1 | |
Completed |
NCT01771237 -
HIV Prevention Among Vulnerable Male Youth
|
N/A | |
Completed |
NCT00360555 -
A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360529 -
24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360243 -
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
|
Phase 3 | |
Recruiting |
NCT05456919 -
Quality of Sexual Function in BRCA Mutated Women
|
||
Terminated |
NCT01040208 -
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress
|
Phase 3 | |
Terminated |
NCT01057901 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
|
Phase 3 |